Cargando…
Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker
Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the motor symptoms. However, it does not affect...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435426/ https://www.ncbi.nlm.nih.gov/pubmed/34328686 http://dx.doi.org/10.1111/jcmm.16827 |
_version_ | 1783751790156578816 |
---|---|
author | Chis, Aimee Rodica Moatar, Alexandra Ioana Dijmarescu, Cristina Rosca, Cecilia Vorovenci, Ruxandra Julia Krabbendam, Inge Dolga, Amalia Bejinar, Cristina Marian, Catalin Sirbu, Ioan Ovidiu Simu, Mihaela |
author_facet | Chis, Aimee Rodica Moatar, Alexandra Ioana Dijmarescu, Cristina Rosca, Cecilia Vorovenci, Ruxandra Julia Krabbendam, Inge Dolga, Amalia Bejinar, Cristina Marian, Catalin Sirbu, Ioan Ovidiu Simu, Mihaela |
author_sort | Chis, Aimee Rodica |
collection | PubMed |
description | Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the motor symptoms. However, it does not affect the progression of the disease and its long‐term use triggers severe complications. There are no bona fide biomarkers for monitoring the patients’ response to LevoDopa and predicting the efficacy of levodopa treatment. Here, we have combined qPCR microRNA array screening with analysis of validated miRs in naïve versus Levodopa‐treated PD patients. We have identified plasma miR‐19b as a possible biomarker for LevoDopa therapy and validated this result in human differentiated dopaminergic neurons exposed to LevoDopa. In silico analysis suggests that the LevoDopa‐induced miR‐19b regulates ubiquitin‐mediated proteolysis. |
format | Online Article Text |
id | pubmed-8435426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84354262021-09-15 Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker Chis, Aimee Rodica Moatar, Alexandra Ioana Dijmarescu, Cristina Rosca, Cecilia Vorovenci, Ruxandra Julia Krabbendam, Inge Dolga, Amalia Bejinar, Cristina Marian, Catalin Sirbu, Ioan Ovidiu Simu, Mihaela J Cell Mol Med Original Articles Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the motor symptoms. However, it does not affect the progression of the disease and its long‐term use triggers severe complications. There are no bona fide biomarkers for monitoring the patients’ response to LevoDopa and predicting the efficacy of levodopa treatment. Here, we have combined qPCR microRNA array screening with analysis of validated miRs in naïve versus Levodopa‐treated PD patients. We have identified plasma miR‐19b as a possible biomarker for LevoDopa therapy and validated this result in human differentiated dopaminergic neurons exposed to LevoDopa. In silico analysis suggests that the LevoDopa‐induced miR‐19b regulates ubiquitin‐mediated proteolysis. John Wiley and Sons Inc. 2021-07-30 2021-09 /pmc/articles/PMC8435426/ /pubmed/34328686 http://dx.doi.org/10.1111/jcmm.16827 Text en © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Chis, Aimee Rodica Moatar, Alexandra Ioana Dijmarescu, Cristina Rosca, Cecilia Vorovenci, Ruxandra Julia Krabbendam, Inge Dolga, Amalia Bejinar, Cristina Marian, Catalin Sirbu, Ioan Ovidiu Simu, Mihaela Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker |
title | Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker |
title_full | Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker |
title_fullStr | Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker |
title_full_unstemmed | Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker |
title_short | Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker |
title_sort | plasma hsa‐mir‐19b is a potential levodopa therapy marker |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435426/ https://www.ncbi.nlm.nih.gov/pubmed/34328686 http://dx.doi.org/10.1111/jcmm.16827 |
work_keys_str_mv | AT chisaimeerodica plasmahsamir19bisapotentiallevodopatherapymarker AT moataralexandraioana plasmahsamir19bisapotentiallevodopatherapymarker AT dijmarescucristina plasmahsamir19bisapotentiallevodopatherapymarker AT roscacecilia plasmahsamir19bisapotentiallevodopatherapymarker AT vorovenciruxandrajulia plasmahsamir19bisapotentiallevodopatherapymarker AT krabbendaminge plasmahsamir19bisapotentiallevodopatherapymarker AT dolgaamalia plasmahsamir19bisapotentiallevodopatherapymarker AT bejinarcristina plasmahsamir19bisapotentiallevodopatherapymarker AT mariancatalin plasmahsamir19bisapotentiallevodopatherapymarker AT sirbuioanovidiu plasmahsamir19bisapotentiallevodopatherapymarker AT simumihaela plasmahsamir19bisapotentiallevodopatherapymarker |